Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kall, Meaghan M ^a,b   Coyne, Katherine M ^a   Garrett, Nigel J ^a   Boyd, Aileen E ^a   Ashcroft, Anthony T ^a   Reeves, Iain ^a   Anderson, Jane ^a   Bothamley, Graham H ^a  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT REFERRAL; PREVALENCE; SUBCLINICAL TUBERCULOSIS; THORAX RADIOGRAPHY; TUBERCULOSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ASYMPTOMATIC DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PREVALENCE; URBAN POPULATION; YOUNG ADULT;

EID: 84860501631     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-107     Document Type: Article

References (44)

1. WHO and UNAIDS Policy statement on preventive therapy against tuberculosis in people living with HIV 1998, WHO, Geneva, Switzerland, WHO and UNAIDS.
2. World Health Organization Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings 2010, Department of HIV/AIDS, Stop TB Department, World Health Organization, Geneva, Switzerland, World Health Organization.
3. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, Bossink A, Dheda K, Diel R, Dominguez J, Lipman M, Nemeth J, Ravn P, Winkler S, Huitric E, Sandgren A, Manissero D. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011, 37:100-111.
4. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon-gamma release assays to detect Mycobacterium tuberculosis infection - United States 2010. MMWR 2011, 59(RR05):1-25.
5. Pozniak AL, Collins S, Coyne KM, . on behalf of the British HIV Association guidelines subcommittee BHIVA guidelines for the treatment of TB/HIV Co-infection 2010 2011, BHIVA, London, UK, on behalf of the British HIV Association guidelines subcommittee.
6. Aichelburg MC, Rieger A, Breitenecker F, Pfiztershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009, 48(7):954-962.
7. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt HR, Staszewski S. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008, 22:2471-2479.
8. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM. Poor concordance between interferon-ganna release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009, 9:15.
9. Health Protection Agency HIV in the United Kingdom: 2010 Report 2010, HPA, London, UK, Health Protection Agency.
10. Health Protection Agency Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2010 2010, HPA, London, UK, Health Protection Agency.
11. World Health Organization Global Tuberculosis Control: WHO Report 2010 2010, WHO, Geneva, Switzerland, World Health Organization.
12. Garrett N, Kall M, Ashcroft T, Reeves I, Anderson J, Bothamley G. Evaluation of HIV-infected patients for latent or subclinical tuberculosis with the T-Spot.TB (Elispot) test. HIV Med 2008, 9(Suppl 1):30.
13. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011, 8(1):e1000391.
14. National Institute for Health and Clinical Excellence (NICE) Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2006, Royal College of Physicians, London, UK, National Institute for Health and Clinical Excellence (NICE).
15. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis in HIV infected persons. Cochrane Database Syst Rev 2010, 1:CD000171.
16. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007, 30:728-735.
17. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberty J, Schecter M, Klukowicz AJ, Barry MA, O'Brien RJ. Rifampin and pyrazinamide versus isoniazid for the prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000, 283:1445-1450.
18. van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart M, Keizer S, Borgdorff M, Mensen M, Cobelens F. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 2004, 39:488-496.
19. Pulido F, Peňa JM, Rubio R, Moreno S, González J, Guijarro C, Costa JR, Vázques JJ. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Ann Intern Med 1997, 157:227-232.
20. National Institute for Health and Clinical Excellence (NICE) Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2011, Royal College of Physicians, London, UK, National Institute for Health and Clinical Excellence (NICE).
21. Reid MJA, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource limited settings. Lancet Infect Dis 2009, 9:173-184.
22. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Pharuphak P, Teeratakulpisam N, Phanuphak N, Dung NH, Quy HT, That LH, Varma JK. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010, 362:707-716.
23. Corbett EL, Bandason T, Cheung YB, Munyatta S, Godfrey-Fausett P, Hayes R, Churchyard G, Butterworth A, Mason P. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007, 4(1):e22.
24. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker L-G. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007, 175(1):87-93.
25. Greenberg SD, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994, 193(1):115-119.
26. Hargreaves NJ, Kadzakumanja O, Phiri S, Nyangulu DS, Salaniponi FML, Harries AD, Squire SB. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence?. Int J Tuberc Lung Dis 2001, 5(2):113-122.
27. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, Cole BF, Vuola JM, Tvaroha S, Kreisworth B, Pallangyo K, von Reyn CF. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005, 40(10):1500-1507.
28. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(2):93-102.
29. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010, 51(7):823-829.
30. Rangaka MX, Gideon HP, Wilkisnon KA, Pai M, Mwansa-Kambafilwe J, Maartens G, Glynn JR, Boulle A, Fielding K, Goliath R, Titus R, Mathee S, Wilkinson RJ. No discriminatory value of interferon-gamma release assays added to smear negative HIV-tuberculosis algorithms. Eur Respir J 2012, 39(1):163-171.
31. Volmink J, Woldehanna S. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004, CD000171.
32. Diel R, Goletti D, Ferrara C, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger J-P, Sandgren A, Manissero D. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2010, 37:88-99.
33. Cattamanchi A, Smith R, Steingert KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011, 56:230-238.
34. Horsburgh CR, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, Narita M, Johnson LS, von Reyn CF. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010, 182(3):420-425.
35. United Kingdom Collaborative HIV Cohort Study Group Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. AIDS 2009, 23(18):2507-2515. United Kingdom Collaborative HIV Cohort Study Group.
36. van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, Grant AD. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010, 24(7):1051-1055.
37. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next?. Int J Tuberc Lung Dis 2008, 12(12):1352-1364.
38. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005, 40(5):670-676.
39. Sterling TR, Villarino ME, Borison AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE, . for the TB Trials Consortium PREVENT TB Study Team Three months of rifapentine and isoniazid for latent tuberculosis infection. New Engl J Med 2011, 365:2155-2166. for the TB Trials Consortium PREVENT TB Study Team.
40. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010, 14(4):e292-e297.
41. Aït-Khaled N, Alarcon E, Bissell K, et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis 2009, 13(8):927-935.
42. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006, 12(5):744-751.
43. Bergval IL, Schuitema AR, Klatser PR, Anthony RM. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 2009, 64:515-523.
44. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, Flynn JL, Fortune SM. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011, 43:482-486.